ArticleJournal of gastroenterology2015
Seventeen-year effects of eradicating Helicobacter pylori on the prevention of gastric cancer in patients with peptic ulcer; a prospective cohort study.
Article in Journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Chemoprevention of gastric cancer development afterWorld journal of gastroenterology · 2020Pooled it
- Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2019Pooled it
- Gastric cancer in patients with gastric atrophy and intestinal metaplasia: A systematic review and meta-analysis.PloS one · 2019Pooled it
- Risk Factors for Gastric Cancer: A Systematic ReviewAsian Pacific journal of cancer prevention : APJCP · 2018Pooled it
- The association between vacA or cagA status and eradication outcome of Helicobacter pylori infection: A meta-analysis.PloS one · 2017Pooled it
- Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens.Internal medicine (Tokyo, Japan) · 2017Trial
- Histopathological features of gastric map-like redness under image-enhanced endoscopy.Frontiers in medicine · 2026Article
- Perspectives on gastric cancer: the central role of gastrin in carcinogenesis byFrontiers in oncology · 2026Review
- Gastric Cancer after <italic>Helicobacter pylori</italic> Eradication: Characteristics, Diagnosis, and Management.Digestion · 2025Review
- Review
- Predictors of the Development of Gastric Cancer in Post-Cancers · 2025Article
- Can patients with mild non-neoplastic lesions diagnosed at baseline screening be safely exempt from surveillance: evidence from multicenter community-based cohorts.Science China. Life sciences · 2025Article
- Clinicopathologic Features of Early Gastric Cancer afterCancers · 2024Article
- Article
- Artificial intelligence in theranostics of gastric cancer, a review.Medical review (2021) · 2023Review
- [Clinical Application of the Kyoto Classification of Gastritis].The Korean journal of helicobacter and upper gastrointestinal research · 2023Review
- Endoscopic characteristics and high-risk background mucosa factors of early gastric cancer after helicobacter pylori eradication: a single-center retrospective study.Frontiers in oncology · 2023Article
- Article
- An explainable artificial intelligence system for diagnosingTherapeutic advances in gastroenterology · 2023Article
- Deep learning for gastroscopic images: computer-aided techniques for clinicians.Biomedical engineering online · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe previously reported that eradication of Helicobacter pylori in our cohort of patients with peptic ulcer disease reduced their risk of developing gastric cancer to approximately one-third after a mean follow-up period of 3.4 years (up to 8.6 years). We have now followed these patients for a longer period.
methodsA total of 1,222 consecutive patients with peptic ulcer diseases who completed more than 1-year follow-up after receiving H. pylori eradication therapy were followed with annual endoscopic surveillance for a mean of 9.9 years (as long as 17.4 years).
resultsH. pylori infection was judged cured in 1,030 patients (eradication-success group) but persisted in 192 (eradication-failure group) after initial eradication therapy. In the eradication-failure group, 114 patients received re-treatment at a mean of 4.4 years after the start of follow-up, and 105 of these were cured of infection. Gastric cancer developed in 21 of the 1,030 patients in the eradication-success group and in nine of the 192 in the failure group (p = 0.04). The risk of developing gastric cancer in the eradication-success group (0.21 %/year) was significantly lower than that in the failure group (0.45 %, p = 0.049). The longest interval between the initial H. pylori eradication and the occurrence of gastric cancer was 14.5 years in the eradication-success group and 13.7 years in the eradication-failure group.
conclusionsA prophylactic effect for gastric cancer persists for more than 10 years after H. pylori eradication therapy, but we should be aware that cancer can develop even after that interval.
Indexed as
Identifiers
25351555What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.